publication . Article . 2006

Treatment of New World cutaneous leishmaniasis with miltefosine

Jaime Soto; Jonathan Berman;
Open Access
  • Published: 01 Dec 2006
  • Publisher: Oxford University Press (OUP)
Summary Miltefosine (2.5 mg/kg/day for 28 days) was investigated for treatment of New World cutaneous leishmaniasis in Colombia and Guatemala. The data from a controlled study was remarkably similar to the data of a prior uncontrolled pilot study. In the controlled study, the per-protocol 6-month cure rate for Leishmania panamensis disease was 91% compared with a concomitant placebo cure rate of 38%. In Guatemala, the cure rate for L. braziliensis and L. mexicana disease was ∼50% compared with ∼20% for placebo. In both countries, nausea but not ‘motion sickness’ and vomiting but not diarrhoea were experienced by approximately 30% more miltefosine patients than p...
Persistent Identifiers
Medical Subject Headings: parasitic diseases
free text keywords: Public Health, Environmental and Occupational Health, Parasitology, Infectious Diseases, General Medicine, Cutaneous leishmaniasis, medicine.disease, medicine, Gastroenterology, medicine.medical_specialty, business.industry, business, Miltefosine, medicine.drug, Placebo, Internal medicine, Leishmaniasis, Pharmacotherapy, Nausea, medicine.symptom, Surgery, Concomitant, Vomiting
Related Organizations
Any information missing or wrong?Report an Issue